Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of Buy by Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) has received a consensus rating of “Buy” from the seven research firms that are currently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on the stock in […]

Related Keywords

Immunomodulators Tracir ,Engagers Tractr ,William Blair ,Janux Therapeutics Company Profile ,Nasdaq ,Vanguard Group Inc ,Cantor Fitzgerald ,Blackrock Inc ,Janux Therapeutics Inc ,Janux Therapeutics ,Get Free Report ,Capital Partners ,Therapeutics Stock Down ,Get Free ,Tumor Activatedt Cell Engagers ,Tumor Activated Immunomodulators ,Janux Therapeutics Daily ,